UBS Group Reiterates “CHF 87” Price Target for Novartis (VTX:NOVN)

UBS Group set a CHF 87 target price on Novartis (VTX:NOVN) in a research note issued to investors on Thursday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.

Several other research firms have also weighed in on NOVN. Credit Suisse Group cut their target price on FOX from $51.00 to $45.00 and set an outperform rating on the stock in a research note on Monday, June 3rd. Deutsche Bank reissued a buy rating and issued a $80.00 target price on shares of Bayerische Motoren Werke in a research note on Monday, July 8th. Kepler Capital Markets set a €160.00 ($186.05) target price on Pfeiffer Vacuum Technology and gave the company a buy rating in a research note on Tuesday, May 21st. Morgan Stanley raised their price target on Intact Financial from C$125.00 to C$128.00 in a research report on Thursday, May 30th. Finally, HSBC set a €101.00 ($117.44) price target on Grenke and gave the stock a buy rating in a research report on Thursday, April 25th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of CHF 88.64.

Novartis has a one year low of CHF 72.45 and a one year high of CHF 88.30.

About Novartis

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Further Reading: Dividend Yield

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with's FREE daily email newsletter.